Impax Laboratories

What Impax Laboratories does

Impax Laboratories was a technology-based specialty pharmaceutical company founded in 1993 and headquartered in Hayward, California, focused on controlled-release generic versions of brand-name pharmaceuticals. In 2018, Impax was acquired by Amneal Pharmaceuticals in an all-stock transaction and now operates as a wholly-owned subsidiary within Amneal (NYSE: AMRX); Impax's independent stock listing on NASDAQ under IPXL has been delisted. The combined entity operates with approximately 2,500 U.S. employees and 1 million sq. ft. of advanced U.S. manufacturing capacity, supplemented by manufacturing operations in India and Ireland.

The company's core offering is a 290+ product portfolio spanning three categories: generics (the largest base, credited with an estimated $18B in annual U.S. patient savings based on IQVIA/AAM data), biosimilars (positioned for cancer and other biologics), and specialty pharmaceuticals (differentiated, higher-margin products). Notable recent specialty launches include CREXONT® (Carbidopa and Levodopa Extended-Release Capsules) for Parkinson's disease, launched in 2024, and Brekiya® (dihydroergotamine mesylate autoinjector), launched in 2025 as the first-and-only DHE autoinjector for acute migraine and cluster headache. Differentiated formulation capability is anchored by two proprietary drug delivery technology platforms, GRANDE® (extended-release) and KRONOTEC® (controlled release), which are registered trademarks and serve as architectural differentiators across the portfolio.

The business model is sales-led with enterprise field sales targeting healthcare providers, pharmacies, healthcare systems, and institutional buyers. Products are sold under one-time (volume-based) revenue arrangements through four distribution channels: retail pharmacies, specialty pharmacies, healthcare institutions and providers (direct sales), and healthcare payer/PBM networks for formulary inclusion. Pricing is not publicly disclosed and is determined through payer, PBM, and institutional negotiations. Customers are end-patients with complex conditions and the providers, pharmacies, and payers that serve them. The U.S. is the primary market, with India and Ireland providing manufacturing and regulatory support.

Name

Impax Laboratories

Legal name

Amneal Pharmaceuticals LLC

Website

https://impaxlabs.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Impax Laboratories, founded in 1993, was a specialty pharmaceutical firm focused on controlled-release generics. Acquired by Amneal Pharmaceuticals in 2018, it now operates within Amneal's 290+ product portfolio spanning generics, biosimilars, and specialty medicines including CREXONT and Brekiya.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Complex Generics (e.g., inhalation, transdermal, liposomal) (HLAIABAB), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Specialty medications
• Controlled-release formulations
• Biosimilar development
• Drug delivery technology

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Supply Chain, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals: Manufacture and sale of generic medications across 290+ products. Revenue generated through volume-based sales to pharmacies, healthcare systems, and distributors. The company estimates $18B in annual savings for U.S. patients through generic drug access.
2. Specialty Pharmaceuticals: Differentiated specialty medications including CREXONT® (Carbidopa and Levodopa Extended-Release Capsules) for Parkinson's disease. Higher-margin specialty products with focused sales efforts on specific therapeutic areas.
3. Biosimilars: Development and commercialization of biosimilar medications for cancer treatment and other therapeutic areas. Positioned as cost-effective alternatives to reference biologics.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Impax Laboratories developed, manufactured, and marketed technology-based specialty pharmaceutical products, with a historical focus on controlled-release generic versions of brand-name pharmaceuticals. Following its 2018 acquisition by Amneal Pharmaceuticals, Impax's operations contribute to a portfolio of 290+ generic, specialty, and biosimilar medicines supported by proprietary drug delivery technology platforms (GRANDE® and KRONOTEC®) for extended-release and controlled-release formulations.

Product overview

Amneal Pharmaceuticals is a pharmaceutical manufacturing company offering a diversified portfolio of 290+ high-quality generic, biosimilar, and specialty medicines. The portfolio spans three main product categories: Generics (covering wide-ranging conditions), Biosciences/Biosimilars (focused on cancer treatments and biologics), and Specialty Medicines (including Parkinson's disease treatment CREXONT and migraine treatment Brekiya). The company also develops proprietary drug delivery technologies including GRANDE and KRONOTEC platforms. The overall offering represents a unified pharmaceutical manufacturing and development capability rather than a software platform architecture.

Differentiator

Problem solved

Functional benefit

Brands

• CREXONT: Carbidopa and Levodopa Extended-Release Capsules for treatment of Parkinson's disease.
• Brekiya
• GRANDE
• KRONOTEC

Products and services

• CREXONT (Carbidopa and Levodopa) Extended-Release Capsules Extended-release capsules for the treatment of Parkinson's disease, designed to give patients more 'Good On' time. For healthcare providers, hospitals, and Parkinson's patients.
• Brekiya (dihydroergotamine mesylate) autoinjector Autoinjector for the acute treatment of migraine and cluster headache episodes in adults. First-and-only DHE (dihydroergotamine mesylate) autoinjector. For healthcare providers, specialty pharmacies, and adult patients.
• Generics Portfolio Portfolio of generic pharmaceutical products covering a wide range of therapeutic conditions. Estimated to save people in the U.S. an estimated $18B annually according to IQVIA market share data. For pharmacies, healthcare systems, and distributors.
• Biosciences/Biosimilars Biosimilar products for fighting cancer and other conditions, providing more affordable biologic alternatives to reference biologics. For healthcare providers, payers, and patients.
• Specialty Medicines Specialty pharmaceutical products addressing complex health conditions including Parkinson's disease (CREXONT) and migraine/cluster headache (Brekiya). Distributed via specialty pharmacies and focused sales efforts.

Quantifiable outcome

• $18B annual savings for U.S. patients through access to generic medicines
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Apotex: Canadian-based generics manufacturer with a portfolio of 300+ generic molecules sold across the U.S. Comparable in scale and product breadth to Amneal/Impax, with similar exposure to U.S. retail and institutional channels.
• Viatris (formerly Mylan + Upjohn): Global generics and specialty pharmaceutical company formed from Mylan and the Upjohn division of Pfizer. Directly comparable portfolio mix of branded specialty, generics, and biosimilars with similarly diversified U.S. manufacturing and global commercial reach.
• Aurobindo Pharma: India-headquartered generics manufacturer with significant U.S. footprint including oral solids, injectables, and biosimilars. Comparable generics scale, U.S. manufacturing expansion, and pricing-pressure dynamics.
• Endo International (now Mallinckrodt generics / Par Health): Specialty and generics pharmaceutical company with overlapping Parkinson-related, migraine-related, and complex generics exposure. Competes with Amneal/Impax in specialty neurology, pain, and generics distribution channels.
• Sun Pharmaceutical Industries: India-headquartered global specialty and generics manufacturer with extensive U.S. generic operations, complex generics capability, and specialty franchise. Similar business model combining high-volume generics with differentiated specialty and controlled-release formulations.
• Hikma Pharmaceuticals: U.S.-listed generics and specialty injectable manufacturer. Comparable in terms of U.S. generics footprint, injectables capability, and investment in domestic/regulated manufacturing capacity.
• Dr. Reddy's Laboratories: India-based integrated pharmaceutical company with a substantial U.S. generics and biosimilars business. Directly comparable generics portfolio depth, complex generics capability, and biosimilar pipeline intent.

Broad incumbents

• Sandoz (Novartis generics division): One of the largest global generic and biosimilar manufacturers, spun out of Novartis. Competes head-to-head in generics and biosimilars with a stronger European orientation but overlapping U.S. generics exposure.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a significant specialty and biosimilars franchise. Direct functional overlap with Amneal/Impax across generics, complex generics, specialty, and biosimilars; Teva is a broader incumbent with much greater scale and a global commercial footprint.

Emerging players

• Lannett Company: U.S.-focused generic drug manufacturer with a portfolio of oral solid generics and select specialty products. Smaller in scale than Amneal/Impax but operates in the same U.S. generic prescription channels and competes on overlapping molecules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/AmnealPharma
• YouTubeyoutube.com/channel/UCQ1VlP0GTdfiL_WrJzIlzOQ
• Facebookfacebook.com/people/Amneal-Pharmaceuticals/100076381024161
• LinkedInlinkedin.com/company/impax-laboratories

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impax Laboratories